Sildenafil citrate is under clinical development by Aspargo Laboratories and currently in Phase I for Erectile Dysfunction. According to GlobalData, Phase I drugs for Erectile Dysfunction have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Sildenafil citrate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Sildenafil citrate overview

Sildenafil citrate (ASP-001) is under development for the treatment of erectile dysfunction. It targets phosphodiesterase 5 (PDE5). It is an oral liquid suspension of sildenafil citrate administered through a spray pump that dispenses 12.5 mg of sildenafil citrate per push of the pump or via an individual single liquid unit dispensing 100 mg per unit

Aspargo Laboratories overview

Aspargo Laboratories (Aspargo) is a biopharmaceutical company that develop oral spray designed to treat erectile dysfunction. The company is headquartered in United States.

For a complete picture of Sildenafil citrate’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.